We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Prognostic Factors in Children with HLH Investigated

By LabMedica International staff writers
Posted on 27 Oct 2016
Hemophagocytic lymphohistiocytosis (HLH) is a rare disease characterized by a rapidly fatal hematological disorder usually associated with malignancies and severe infections and it presents with prolonged high fever that could not be controlled by antibiotics.

Other manifestations of HLH are hepatosplenomegaly, cytopenia, widespread infiltration with lymphocytes, and benign-looking histiocytes with hemophagocytosis in the bone marrow, liver, spleen, or lymph nodes. More...
Early diagnosis and combined treatment can effectively control this life-threatening disease.

Scientists at the Guangdong Medical College (Shenzhen, People’s Republic of China) carried out a retrospective analysis on HLH from January 1, 2000, to November 30, 2013. Of the 56 pediatric patients, 35 were boys and 21 were girls with a median age of 4.5 years (range: four months to 12 years) at the onset of HLH. The median duration before diagnosis of HLH was 1.5 weeks (range: one week to six weeks). The most common clinical symptoms observed were fever (100%), hepatomegaly or splenomegaly (95.24%), and pancytopenia (100%).

The team found that characteristic laboratory values presented with increased ferritin (64.29%), triglycerides (78.6%), transaminases (81%), bilirubin (67.5%), lactate dehydrogenase (95.2%), and decreased fibrinogen (61.9%), sodium (40.5%), and potassium (30.9%). Bone marrow aspiration showed hemophagocytosis in 48 cases (85.7%). Among the clinical and laboratory features analyzed, high lactate dehydrogenase (LDH) of greater than 2,000 U/L, high bilirubin of greater than 2 mg/mL, and younger age less than 2 years old at the time of diagnosis indicated worst outcome.

Anemia was observed in 39 patients (five cases with hemoglobin level less than 90 g/L, 27 cases less than 60–89 g/L, seven cases less than 30–59 g/L), neutropenia (neutrophil count less than 1.5×109/L) in 28 patients (22 cases less than 0.5–1.0×109/L, and five cases less than 0.5×109/L, and thrombocytopenia (platelet count less than 100×109/L) in 35 patients (33 cases with platelet count less than 20–99×109/L and two cases with platelet count less than 20×109/L). Examination of bone marrow aspiration showed hemophagocytosis in 48 (85.7%) patients.

The authors concluded that the etiology of HLH is complicated and early diagnosis is difficult. The level of LDH and bilirubin may predict the severity of HLH and depending on the clinical presentation, individualized therapy is needed for different patients. The study was published on October 11, 2016, in the Journal of Blood Medicine.

Related Links:
Guangdong Medical College



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.